New vaccine targets 24 pneumonia strains in adult trial
NCT ID NCT07543198
First seen May 03, 2026 · Last updated May 23, 2026 · Updated 4 times
Summary
This study tested a new vaccine (PCV24) designed to protect against 24 types of pneumococcal bacteria, which can cause pneumonia and other infections. 385 healthy adults aged 18 and older received either the new vaccine or a control. Researchers checked for side effects and measured immune responses 30 days after vaccination. The trial is complete, and results will show how safe and effective the vaccine is.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL INFECTIOUS DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Shaanxi Provincial Center for Disease Control and Prevention
Xi'an, Shaanxi, China
Conditions
Explore the condition pages connected to this study.